Literature DB >> 2289988

A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients.

C E Hack1, J H Nuijens, R J Strack van Schijndel, J J Abbink, A J Eerenberg, L G Thijs.   

Abstract

Previously we studied levels of the cytokine IL-6 and activation of the complement and contact system and of neutrophils in a group of 48 patients with sepsis. Some of these inflammatory parameters appeared to be associated with a poor prognosis. Here we report on the relationships of C4a and C3a (complement activation products), of factor XII and prekallikrein (contact system proteins), of elastase (a protease released by activated neutrophils) and of the cytokine IL-6 to hemodynamic and biochemical parameters measured in those 48 patients at the time of admission to the Intensive Care Unit. No significant correlations between any inflammatory parameter and either systemic vascular resistance or cardiac index were found. Mean arterial pressure significantly correlated with both factor XII and prekallikrein levels. Lactate correlated with C3a and C4a, with elastase, and in particular, with IL-6, whereas it did not correlate with either factor XII or prekallikrein. Platelet numbers inversely correlated with both C3a and C4a, as well as with elastase and IL-6, whereas they positively correlated with factor XII and prekallikrein. Based on these findings we propose a model for the interplay of these inflammatory mediators in the pathogenesis of sepsis. This model takes into consideration the occurrence of capillary leakage, shock, disseminated intravascular coagulation, thrombocytopenia and of acute phase reactions in sepsis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289988     DOI: 10.1007/bf01709698

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  34 in total

1.  Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.

Authors:  J H Nuijens; C C Huijbregts; M Cohen; G O Navis; A de Vries; A J Eerenberg; J C Bakker; C E Hack
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

Review 2.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

3.  Serum complement levels in bacteremia due to gram-negative organisms.

Authors:  W R McCabe
Journal:  N Engl J Med       Date:  1973-01-04       Impact factor: 91.245

Review 4.  Anaphylatoxins: possible roles in disease.

Authors:  W Vogt
Journal:  Complement       Date:  1986

5.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

6.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 7.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

8.  Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase.

Authors:  L A Smedly; M G Tonnesen; R A Sandhaus; C Haslett; L A Guthrie; R B Johnston; P M Henson; G S Worthen
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; R S Cotran; M A Gimbrone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  4 in total

1.  Monitoring of immunotherapy with cytokines or monoclonal antibodies.

Authors:  C Erik Hack
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

2.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?

Authors:  B Leithäuser; F R Matthias; U Nicolai; R Voss
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

Review 3.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 4.  Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation.

Authors:  A R Webb; M G Mythen; D Jacobson; I J Mackie
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.